ArticleEuropean journal of case reports in internal medicine2025
Slow Evolution of Non-Familial Autoimmune Polyglandular Syndrome Type II in A 54-Year-Old Female, First Presenting with Addison's Disease, then Hashimoto's Thyroiditis, which then Transitioned to Graves' Disease and then the Development of Type 1 Diabetes.
Article in European journal of case reports in internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autoimmune polyglandular syndrome type II (APS-II) is a rare disorder defined by primary adrenal insufficiency in combination with autoimmune thyroid disease and/or type 1 diabetes mellitus. The dynamic nature of autoimmunity complicates diagnosis and management. Case report: A 54-year-old woman presented in 2009 with Addison's disease, confirmed by very low cortisol and markedly elevated adrenocorticotropic hormone, despite negative adrenal antibodies. She remained stable on steroid replacement until 2019, when she developed hypothyroidism with elevated thyroid-stimulating hormone (TSH) and positive thyroglobulin antibodies, consistent with Hashimoto's thyroiditis. In 2023, she experienced new hyperthyroid symptoms with suppressed TSH, elevated free thyroxine, positive thyroid-stimulating immunoglobulin, and ultrasound evidence of diffuse hypervascularity, confirming Graves' disease. Concurrent screening revealed haemoglobin A1c 6.2% and positive GAD65 antibody, consistent with a risk of autoimmune diabetes, although without overt hyperglycaemia. LEARNING POINTS:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.